

# Hemizyosity for *SMCHD1* in Facioscapulohumeral Muscular Dystrophy Type 2: Consequences for 18p Deletion Syndrome

Richard J. L. F. Lemmers,<sup>1\*</sup> Marlinde L. van den Boogaard,<sup>1</sup> Patrick J. van der Vliet,<sup>1</sup> Colleen M. Donlin-Smith,<sup>2</sup> Sharon P. Nations,<sup>3</sup> Claudia A. L. Ruivenkamp,<sup>4</sup> Patricia Heard,<sup>5</sup> Bert Bakker,<sup>4</sup> Stephen Tapscott,<sup>6</sup> Jannine D. Cody,<sup>5</sup> Rabi Tawil,<sup>2</sup> and Silvère M. van der Maarel<sup>1</sup>

<sup>1</sup>Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands; <sup>2</sup>Neuromuscular Disease Unit, Department of Neurology, University of Rochester Medical Center, Rochester, New York; <sup>3</sup>Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas; <sup>4</sup>Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; <sup>5</sup>University of Texas Health Science Center at San Antonio, Chromosome 18 Research Center, San Antonio, Texas; <sup>6</sup>Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington

Received 23 December 2014; accepted revised manuscript 20 March 2015.

Published online 27 March 2015 in Wiley Online Library (www.wiley.com/humanmutation). DOI: 10.1002/humu.22792

**ABSTRACT:** Facioscapulohumeral muscular dystrophy (FSHD) is most often associated with variegated expression in somatic cells of the normally repressed *DUX4* gene within the D4Z4-repeat array. The most common form, FSHD1, is caused by a D4Z4-repeat array contraction to a size of 1–10 units (normal range 10–100 units). The less common form, FSHD2, is characterized by D4Z4 CpG hypomethylation and is most often caused by loss-of-function mutations in the structural maintenance of chromosomes hinge domain 1 (*SMCHD1*) gene on chromosome 18p. The chromatin modifier *SMCHD1* is necessary to maintain a repressed D4Z4 chromatin state. Here, we describe two FSHD2 families with a 1.2-Mb deletion encompassing the *SMCHD1* gene. Numerical aberrations of chromosome 18 are relatively common and the majority of 18p deletion syndrome (18p-) cases have, such as these FSHD2 families, only one copy of *SMCHD1*. Our finding therefore raises the possibility that 18p- cases are at risk of developing FSHD. To address this possibility, we combined genome-wide array analysis data with D4Z4 CpG methylation and repeat array sizes in individuals with 18p- and conclude that approximately 1:8 18p- cases might be at risk of developing FSHD.

Hum Mutat 36:679–683, 2015. © 2015 Wiley Periodicals, Inc.

**KEY WORDS:** FSHD; *SMCHD1*; epigenetic modifier; D4Z4; epiallele

Individuals with facioscapulohumeral muscular dystrophy (FSHD; MIM #158900 [FSHD1] and MIM #158901 [FSHD2]) have progressive and often asymmetric muscle weakness affecting the face, shoulder, and upper arms, followed by involvement of the distal and proximal lower extremities [Padberg, 1982; Tawil and van der Maarel, 2006]. These symptoms are associated with a higher probability of skeletal muscle expression of the *DUX4* retrogene (MIM #606009) that is normally repressed in somatic tissue [Snider et al., 2010]. There are at least two genetically distinct causes of FSHD that are clinically indistinguishable. The most common form, FSHD1, is caused by a variant of the polymorphic D4Z4 macrosatellite repeat array on chromosome 4 that is between 1 and 10 units [Wijmenga et al., 1992]. In unaffected individuals, this polymorphic repeat array ranges between 11 and 100 D4Z4 units and is heavily CpG methylated in somatic tissue, thereby repressing expression of the region [van Overveld et al., 2003]. The shorter array in individuals with FSHD1 is insufficient to maintain the repressed chromatin state necessary for sustaining repression of the *DUX4* retrogene expression. The less common form, FSHD2, is also characterized by a partial loss of CpG methylation at D4Z4 but with repeat array sizes >10 units and is usually caused by mutations in the structural maintenance of chromosomes hinge domain 1 gene (*SMCHD1*; MIM #614982) on chromosome 18p [van Overveld et al., 2003; Lemmers et al., 2012; Larsen et al., 2014]. *SMCHD1* is a chromatin modifier that binds to the D4Z4-repeat array and is necessary to maintain a repressed D4Z4 chromatin state in somatic cells. Each of 3.3 kb large D4Z4 units contains a copy of the double homeobox 4 (*DUX4*) retrogene [Gabriels et al., 1999]. In FSHD1, with the short D4Z4-repeat array, or in FSHD2 with heterozygous *SMCHD1* mutations, either cause leads to a partial derepression of the D4Z4-repeat array in somatic cells. This derepression is marked by D4Z4 hypomethylation, a partial loss of repressive chromatin marks and other chromatin changes and the sporadic expression of *DUX4* in a small set of muscle nuclei [van Overveld et al., 2003; Zeng et al., 2009; Balog et al., 2012; Geng et al., 2012].

However, either mechanism, D4Z4 short repeat sizes, or *SMCHD1* mutations, leading to depression of D4Z4 by themselves are not sufficient to cause FSHD. The D4Z4-embedded *DUX4* retrogene requires a polyadenylation signal in the 3' untranslated region to produce a stable transcript and hence *DUX4* protein in somatic cells [Lemmers et al., 2010a]. This *DUX4* polyadenylation signal can only be found immediately distal to the last *DUX4* copy, but

Additional Supporting Information may be found in the online version of this article.

Contract grant sponsors: European Community's Seventh Framework Programme (FP7/2007-2013; grant agreement number 2012-305121); "Integrated European -omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases (NEUROMICS); The Prinses Beatrix Spierfonds (W.0R12-20); Spieren voor Spieren; NIH NIAMS AR066248; NIH NCRR UL1RR024160; the FSHD Global Research Foundation; the Chromosome 18 Registry and Research Society.

Communicated by Stephen Robertson

\*Correspondence to: Richard J. L. F. Lemmers, Leiden University Medical Center, Department of Human Genetics, Albinusdreef 2, Leiden 2333 ZA, The Netherlands. E-mail: r.j.l.f.lemmers@lumc.nl

its existence is polymorphic in the population and is only found on 4qA-type chromosomes. 4qB chromosomes, that are equally common, or 10q chromosomes that contain a highly homologous copy of the D4Z4-repeat array, do not have a *DUX4* polyadenylation signal [Lemmers et al., 2002; Lemmers et al., 2004; Lemmers et al., 2010a]. Thus, digenic inheritance of a short D4Z4-repeat array in *cis* with a *DUX4* polyadenylation signal in FSHD1, or a heterozygous *SMCHD1* mutation and a *DUX4* polyadenylation signal in FSHD2, are both mechanisms for the development of FSHD [Lemmers et al., 2010a, 2012].

We previously reported that the average repeat array size of the 4qA (i.e., *DUX4* producing) chromosome in FSHD2 patients is most often between 11 and 16 units, which is at the lower end of the repeat size spectrum of 4qA chromosomes in control individuals (Supp. Fig. S1) [de Greef et al., 2010; Lemmers et al., 2014]. We define FSHD2 patients by a methylation level of <25% measured by Southern blotting at the methylation-sensitive *FseI* restriction site in D4Z4, a threshold that has been instrumental in identifying *SMCHD1* as FSHD2 disease gene [Lemmers et al., 2012; Sacconi et al., 2013; Lemmers et al., 2014]. In our recent *SMCHD1* mutation screen in affected individuals with *FseI* methylation levels <25%, we showed that mutations that do not disrupt the open-reading frame (ORF) are more deleterious than those that introduce a premature stop codon [Lemmers et al., 2014]. This conclusion was based on the difference in D4Z4 hypomethylation for the two types of mutation. We found a significant correlation between the cumulative number of all D4Z4-repeat units in the arrays on chromosomes 4 and 10 and the average methylation of the D4Z4 repeats in controls and FSHD patients. This correlation allowed us to define the Delta1 value, which is the observed CpG methylation level at this site in D4Z4 minus the predicted methylation based on control individuals. The average Delta1 in controls is about zero and ranges between -13% and 17% (5th and 95th percentile, respectively), whereas in carriers of an *SMCHD1* mutation this value is about -30% and ranges between -42% and -22% (5th and 95th percentile, respectively) [Lemmers et al., 2014]. Therefore, Delta1 value represents the methylation defect corrected for the size of the D4Z4-repeat array, emphasizing the strong effect of *SMCHD1* mutations on D4Z4 methylation. We also introduced the Delta2 value, which is the observed methylation minus the predicted methylation based on *SMCHD1* mutation carriers and reveals the significance of the mutation [Lemmers et al., 2014]. *SMCHD1* mutations that preserve the ORF most probably result in a dominant negative type mechanism and lead to the lowest Delta1 value, and a negative Delta2 value in somatic cells. ORF-disrupting *SMCHD1* mutations seem to be associated with nonsense-mediated RNA decay suggesting a haploinsufficiency type mechanism and are associated with lesser degrees of D4Z4 CpG hypomethylation resulting in positive Delta2 values. The observation that both the nature of the *SMCHD1* mutation and the size of the D4Z4-repeat array determines the D4Z4 methylation and the disease severity in FSHD2, led to a model in which haploinsufficiency causing mutations require medium short D4Z4 arrays (most often in the range of 11–16 units) to cause FSHD2, whereas dominant negative *SMCHD1* mutations can also cause FSHD2 with larger 4qA array sizes (Supp. Fig. S1) [Lemmers et al., 2014]. Thus, while establishing *FseI* methylation and Delta values are not standard operating procedures in diagnostic settings, these values have contributed to our understanding of FSHD pathogenesis.


In approximately 15% of the FSHD2 families, identified by phenotype and D4Z4 hypomethylation, we could not identify a mutation in *SMCHD1* [Lemmers et al., 2012, 2014]. In six out of 10 of these families, Sanger sequencing of *SMCHD1* in the index case did not reveal a causal variant but showed the absence of heterozygous

SNPs in all of the 48 exons and flanking sequences. These families were subjected to whole-exome sequencing and genome-wide array analysis.

The first family (Rf898) reported in this study came to our attention because of classical features of FSHD, whereas FSHD1 was excluded by D4Z4-repeat array sizing (Fig. 1A; Supp. Table S1). The index case (898.205) was diagnosed at the age of 49 years when he presented with difficulty lifting his arms overhead. In retrospect, he recalls having shoulder difficulties when he was 12 years of age. His physical examination showed a combination of facial weakness, scapular winging, and mild foot dorsiflexor weakness as well as mild abdominal muscle weakness. Two additional family members (898.202, 898.301) were moderately affected with similar clinical features. Subject 898.202 was asymptomatic but had definite signs of FSHD with scapular weakness, foot dorsiflexion weakness, and mild abdominal muscle weakness when examined at the age of 65 years. Her son (898.301) reports symptom onset at the age of 13 years with clear signs of FSHD when examined at the age of 36 years (Supp. Table S1). All carry an 11 units D4Z4-repeat array on a 4qA chromosome containing a *DUX4* polyadenylation site. Methylation analysis provided evidence for reduced D4Z4 methylation levels and Delta1 values consistent with FSHD2 in all three affected individuals, but also in two unaffected individuals. Subject 898.303 carries the same 11 unit 4qA allele as his affected father, reports shoulder pain and weakness since the age of 24 years, but shows no clear signs of weakness on examination at the age of 36 years. An EMG study, however, showed myopathic units in his supraspinatus and cervical paraspinous muscles. Individual 898.204 is unaffected at the age of 59 years, but carries a 35 unit repeat array on a permissive 4qA allele, which appears to be too long to be pathogenic based on previous findings in carriers of a haploinsufficiency causing *SMCHD1* mutation [Lemmers et al., 2014]. *SMCHD1* mutation analysis by Sanger sequencing failed to identify potentially damaging variants. Whole-exome sequencing on 898.301 and 898.303 failed to identify the causative gene, but extended the region of homozygosity into several *SMCHD1* neighboring genes, suggestive of a heterozygous deletion of the *SMCHD1* locus. Subsequently, we performed a genome-wide array analysis in these subjects and identified a 1.2-Mb deletion that spans the *METTL4*, *NDC80*, *SMCHD1*, *EMILIN2*, and *LPIN2* genes (Fig. 1B). This deletion was confirmed in subjects 898.202, 898.204, and 898.205 and this variant was submitted to the Leiden Open Variation Database (<http://databases.lovd.nl/shared/variants/SMCHD1>).

In the second family (Rf929), we identified two FSHD individuals carrying a 13 D4Z4 unit repeat array on 4qA and CpG hypomethylation at D4Z4 suggesting FSHD2 (Fig. 1C; Supp. Table S1). The index case's (929.201) initial complaints were difficulty with his proximal shoulders in his late 20s but was not fully evaluated until the age of 60 years when he presented with facial weakness, shoulder and upper extremity weakness, and foot dorsiflexor weakness. One sister (929.204) is also similarly affected, whereas his other sister (929.206) is asymptomatic and clinically unaffected. By array analysis in individual 929.201, we identified the same interstitial chromosome 18p deletion including *SMCHD1* as was found in family Rf898 (Fig. 1D). This 1.2 Mb deletion was confirmed in affected individual 929.204.

Both families reside in the same state in the US and although these two families are not known to be related, the observation that they carry the same interstitial 18p deletion suggest otherwise. Detailed SNP analysis on chromosome 18 showed that the SNP difference between nephews 898.301 and 898.303 is 1.8% and the difference between 898.301 (or 898.303) and 929.201 is 4.9%, whereas the average difference at chromosome 18 between unrelated individuals is usually >15% (CAL Ruivenkamp, personal communication),



**Figure 1.** **A:** Pedigree of family Rf898, showing three affected individuals (898.202, 898.205, and 898.301) all carrying an 11 unit D4Z4-repeat array on chromosome 4qA (11A) and a partial loss of D4Z4 CpG methylation. The index case (arrow) and the individuals that have been analyzed on the SNP array (asterisk) are indicated. The key indicates the individual ID, the different methylation values (measured methylation; OM, Delta1;  $\delta 1$  and Delta2;  $\delta 2$ ) and the D4Z4-repeat array type and sizes in units on both chromosomes 4 (4-1 and 4-2). **B:** Array plots of chromosome 18. A 1.2-Mb deletion in 18p11.32p11.31 was detected in patients 898.301 and 898.303 (arr[hg19] 18p11.32p11.31[1829674-3039186]x1). The deletion is marked by four panels showing from top to bottom: the Copy Number State, the Weighted Log2 Ratio, the Allele Peaks and the genes. **C:** Pedigree of family Rf929, showing two affected individuals (929.201 and 929.204) both carrying a 13 unit D4Z4-repeat array on chromosome 4qA and a loss of D4Z4 CpG methylation. **D:** Array analysis of patient 929.201 presenting a 1.2-Mb deletion in 18p11.32p11.31 (arr[hg19] 18p11.32p11.31[1844188-3039186]x1).


strongly suggesting that both families are related. Array analysis in the remaining four FSHD2 families that showed the absence of heterozygous SNPs in all 48 *SMCHD1* exons and flanking sequences did not reveal evidence for a deletion in the *SMCHD1* locus.

Although one third of all identified *SMCHD1* mutations in FSHD2 most probably lead to haploinsufficiency, *SMCHD1* was not known as a dosage sensitive gene. Our current study emphasizes that monosomy of *SMCHD1* can cause familial FSHD2, although we cannot rule out that genetic variants in other (currently unknown) epigenetic modifiers of D4Z4 are shared between both families. We identified two families with five affected family members who all carry the same 1.2 Mb 18p microdeletion in combination with a D4Z4-repeat array with 11 or 13 units on a 4qA chromosome. This finding also corroborates our previous study in which we show that haploinsufficiency causing *SMCHD1* mutations in general result in positive Delta2 values, suggestive of a less deleterious outcome [Lemmers et al., 2014]. The Delta2 value in the seven carriers of the *SMCHD1* deletion varied between 1% and 7%.

None of the other genes within the microdeletion have been reported to be sensitive to hemizyosity. Homozygous mutations in lipin 2 (*LPIN2*) have been associated with Majeed syndrome, characterized by chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anemia [Ferguson et al., 2005]. *METTL4* (methyltransferase-like 4) encodes for a putative methyltransferase of unknown function, whereas *NDC80* encodes a central component of the kinetochore protein complex necessary for proper chromosome segregation and spindle checkpoint signaling [Martin-Lluesma et al., 2002].

Structural and numerical aberrations of the short arm of chromosome 18 are relatively common among the chromosomal rearrangement syndromes. The incidence of monosomy 18p is estimated at about 1:50,000 newborns worldwide, and although the dysmorphic features in 18p deletion syndrome (18p-) individuals is not very uniform, muscular dystrophy has not been reported [Turleau, 2008]. Given the association of *SMCHD1* mutations with FSHD and the identification of two families carrying a deletion of *SMCHD1*, it raises the question whether individuals with 18p- are at increased risk of developing FSHD when also carrying a chromosome 4q that contains a *DUX4* polyadenylation signal.

To address this possibility, analysis of CGH array data from 83 individuals with 18p- showed that *SMCHD1* was hemizygous in all but one case [Sebold et al., 2015]. Subsequent CpG methylation analysis of the cases with *SMCHD1* deletion confirmed a reduced methylation at D4Z4 in 72/82 cases (Fig. 2A and B), suggesting that individuals with 18p- have a similar degree of D4Z4 chromatin relaxation as individuals with FSHD2. Previously, we showed that 4qA chromosomes (containing a *DUX4* polyadenylation signal) and 4qB chromosomes (without *DUX4* polyadenylation signal) are almost equally common in the Caucasian and Asian populations, whereas 4qA is the most common chromosome 4 variant in the African population [Lemmers et al., 2010b]. This suggests that about 25% of 18p- individuals carry two 4qB chromosomes and are therefore not at risk for developing FSHD. In two recent studies, we analyzed the D4Z4-repeat array size and haplotype distribution in control individuals [Schaap et al., 2013; Lemmers et al., 2014]. These results showed that 20 out of 159 independent 4A161 chromosomes, the



**Figure 2.** **A:** Chromosome content of individuals with 18p-. The black box around the chromosome ideogram across the top of the figure indicates the region of the chromosome shown below. The study number of each participant is aligned to the left of their data. The intact region of the chromosome is shown as individual gray bars. The breakpoint region is shown in darker gray and regions of duplication are shown as black. The vertical line indicates the location of the *SMCHD1* gene. **B:** The methylation value measured at D4Z4 for control individuals (disomic 18p), individuals that carry an *SMCHD1* mutation (FSHD2) and 18p- individuals that have a deletion of the *SMCHD1* gene (18p-). The box extends from the 25th to 75th percentiles, and the line in the middle of the box is plotted at the median, the whiskers are at the 2.5th and 97.5th percentiles. **C:** Distribution of D4Z4-repeat array sizes on 159 independent 4A161 chromosomes in European control individuals [Schaap et al., 2013; Lemmers et al., 2014].

most common risk allele for FSHD in the Caucasian population accounting for 79% of all 4qA alleles [Lemmers et al., 2010b], had repeat arrays of  $\leq 16$  units, which gives an estimated incidence of 12.6% (Fig. 2C). Because half of the chromosomes 4 are of the 4qB variant, about 12.6% (one in eight) of individuals in the Caucasian population with 18p- carry a medium-short 4qA array and might therefore be at risk for FSHD. To investigate this possibility, we performed accurate D4Z4-repeat array sizing in 19 individuals with 18p- that were selected on the basis that they carried a 4A161 allele and had D4Z4 hypomethylation and we found that two individuals carried an array  $\leq 16$  units and may have an increased risk of developing FSHD (Supp. Fig. S2; Supp. Table S2). Individual 18p-14 carries a 13 unit repeat array and is 27 years old, whereas 18p-37 carries a 15 unit repeat and is 24 years old. At this time, we do not have information about these individuals' clinical status. Contractions on other 4qA alleles, such as 4A159, 4A168, and 4A166H, may also confer a risk to FSHD [Lemmers et al., 2010a]. However, these alleles are much less common than the 4A161 allele [Lemmers et al., 2010b], and therefore only increase the FSHD risk in the 18p- patient population by approximately 1.5%.

## Conclusion

We report heterozygous deletions of *SMCHD1* in two distantly related FSHD2 families and therefore 18p- deletions may constitute a risk factor for FSHD. While other genetic and epigenetic risk factors are likely to contribute to disease penetrance, in order to be at an increased risk of developing FSHD2, two other factors also must be present. First, the presence of a chromosome 4qA containing

a *DUX4* polyadenylation signal and second, the size of the D4Z4-repeat array with array sizes at the lower end of the normal repeat size spectrum being more sensitive to *SMCHD1* hemizyosity than longer arrays.

## Acknowledgment

The authors thank all individuals with FSHD and 18p- as well as their family members for participating in this study.

## References

- Balog J, Thijssen PE, de Greef JC, Shah B, van Engelen BG, Yokomori K, Tapscott SJ, Tawil R, van der Maarel SM. 2012. Correlation analysis of clinical parameters with epigenetic modifications in the DUX4 promoter in FSHD. *Epigenetics* 7:579–584.
- de Greef JC, Lemmers RJ, Camano P, Day JW, Sacconi S, Dunand M, van Engelen BG, Kiuru-Enari S, Padberg GW, Rosa AL, Desnuelle C, Spuler S, et al. 2010. Clinical features of facioscapulohumeral muscular dystrophy 2. *Neurology* 75:1548–1554.
- Ferguson PJ, Chen S, Tayeh MK, Ochoa L, Leal SM, Pelet A, Munnich A, Lyonnet S, Majeed HA, El-Shanti H. 2005. Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). *J Med Genet* 42:551–557.
- Gabriels J, Beckers MC, Ding H, De Vriese A, Plaisance S, van der Maarel SM, Padberg GW, Frants RR, Hewitt JE, Collen D, Belayew A. 1999. Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. *Gene* 236:25–32.
- Geng LN, Yao Z, Snider L, Fong AP, Cech JN, Young JM, van der Maarel SM, Ruzzo WL, Gentleman RC, Tawil R, Tapscott SJ. 2012. DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. *Dev Cell* 22:38–51.
- Larsen M, Rost S, El HN, Ferbert A, Deschauer M, Walter MC, Schoser B, Tacik P, Kress W, Muller CR. 2014. Diagnostic approach for FSHD revisited: *SMCHD1*

- mutations cause FSHD2 and act as modifiers of disease severity in FSHD1. *Eur J Hum Genet*. [Epub ahead of print]
- Lemmers RJ, de Kievit P, Sandkuijl L, Padberg GW, van Ommen GJ, Frants RR, van der Maarel SM. 2002. Facioscapulohumeral muscular dystrophy is uniquely associated with one of the two variants of the 4q subtelomere. *Nat Genet* 32:235–236.
- Lemmers RJ, Goeman JJ, van der Vliet PJ, van Nieuwenhuizen MP, Balog J, Vos-Versteeg M, Camano P, Ramos Arroyo MA, Jerico I, Rogers MT, Miller DG, Upadhyaya M, et al. 2014. Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2. *Hum Mol Genet* 24:659–669.
- Lemmers RJ, Tawil R, Petek LM, Balog J, Block GJ, Santen GW, Amell AM, van der Vliet PJ, Almomani R, Straasheijm KR, Krom YD, Klooster R, et al. 2012. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. *Nat Genet* 44:1370–1374.
- Lemmers RJ, van der Vliet PJ, Klooster R, Sacconi S, Camano P, Dauwerse JG, Snider L, Straasheijm KR, van Ommen GJ, Padberg GW, Miller DG, Tapscott SJ, et al. 2010a. A unifying genetic model for facioscapulohumeral muscular dystrophy. *Science* 329:1650–1653.
- Lemmers RJ, van der Vliet PJ, van der Gaag KJ, Zuninga S, Frants RR, de Knijff P, van der Maarel SM. 2010b. Worldwide population analysis of the 4q and 10q subtelomeres identifies only four discrete duplication events in human evolution. *Am J Hum Genet* 86:364–377.
- Lemmers RJ, Wohlgemuth M, Frants RR, Padberg GW, Morava E, van der Maarel SM. 2004. Contractions of D4Z4 on 4qB subtelomeres do not cause facioscapulohumeral muscular dystrophy. *Am J Hum Genet* 75:1124–1130.
- Martin-Lluesma S, Stucke VM, Nigg EA. 2002. Role of Hec1 in spindle checkpoint signaling and kinetochore recruitment of Mad1/Mad2. *Science* 297:2267–2270.
- Padberg GW. 1982. Facioscapulohumeral disease. PhD thesis, Leiden University, Leiden, The Netherlands.
- Sacconi S, Lemmers RJ, Balog J, van der Vliet PJ, Lahaut P, van Nieuwenhuizen MP, Straasheijm KR, Debipersad RD, Vos-Versteeg M, Salviati L, Casarin A, Pegoraro E, et al. 2013. The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1. *Am J Hum Genet* 93:744–751.
- Schaap M, Lemmers RJ, Maassen R, van der Vliet PJ, Hoogerheide LF, van Dijk HK, Basturk N, de KP, van der Maarel SM. 2013. Genome-wide analysis of macrosatellite repeat copy number variation in worldwide populations: evidence for differences and commonalities in size distributions and size restrictions. *BMC Genomics* 14:143.
- Sebold C, Soileau B, Heard P, Carter E, O'Donnell L, Hale DE, Cody JD. 2015. Whole arm deletions of 18p: medical and developmental effects. *Am J Med Genet A* 167:313–323.
- Snider L, Geng LN, Lemmers RJLF, Kyba M, Ware CB, Nelson AM, Tawil R, Filippova GN, van der Maarel SM, Tapscott SJ, Miller DG. 2010. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. *PLoS Genet* 6:e1001181.
- Tawil R, van der Maarel SM. 2006. Facioscapulohumeral muscular dystrophy. *Muscle Nerve* 34:1–15.
- Turleau C. 2008. Monosomy 18p. *Orphanet J Rare Dis* 3:4.
- van Overveld PG, Lemmers RJ, Sandkuijl LA, Enthoven L, Winokur ST, Bakels F, Padberg GW, van Ommen GJ, Frants RR, van der Maarel SM. 2003. Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. *Nat Genet* 35:315–317.
- Wijmenga C, Hewitt JE, Sandkuijl LA, Clark LN, Wright TJ, Dauwerse HG, Gruter AM, Hofker MH, Moerer P, Williamson R, van Ommen GJ, Padberg GW, et al. 1992. Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. *Nat Genet* 2:26–30.
- Zeng W, de Greef JC, Chen YY, Chien R, Kong X, Gregson HC, Winokur ST, Pyle A, Robertson KD, Schmiesing JA, Kimonis VE, Balog J, et al. 2009. Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD). *PLoS Genet* 5:e1000559.